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Abstract
Background: The aim of this study was to assess the prevalence of sexual dysfunction and to investigate whether there is a change
in sexual dysfunction after six months of methadone maintenance therapy (MMT) compared with baseline.
Patients and Methods: We recruited 150 male Iranian patients from several centers offering methadone maintenance therapy
(MMT). Patients underwent structured interview that consisted of socio-demographic characteristics, drug use, and sexual behavior,
the patients completed the International Index of Erectile Function -15 (IIEF-15) and Sexual Self-efficacy Scale - Erectile Functioning
(SSES-E) tests to assess sexual dysfunction. The statistical method used for analyzing data was the Mann-Whitney U test.
Results: Among men on MMT, 65% had erectile dysfunction (ED). The baseline mean score on the IIEF was 15.55 and, after taking
methadone, that positively increased to 18.12 in the post-assessment. Analysis indicated significant improvement in erectile func-
tion, sexual desire, overall satisfaction, and orgasmic function after methadone maintenance treatment. Also, the baseline means
score on the SSES-E was 86.71, which increased moderately to 94.34 in the post-assessment.
Conclusions: Results showed that sexual dysfunction is a prevalent disorder in opioid-dependent males. Addiction withdrawal
centers should be warned about the dysfunction caused by opioids and, from a clinical perspective, it is imperative that patients
misusing opiates and those treated with methadone are routinely asked about their sexual functioning so that, if indicated, appro-
priate investigations and treatment can be planned. Further, the findings of this study revealed an improvement in some aspects of
sexual dysfunction in patients after six months of methadone maintenance treatment. Thus, explaining to addicts that methadone
causes fewer complications than using illegal drugs can help prevent premature exit from MMT.
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1. Background
Erectile dysfunction refers to men’s failure to achieve
or maintain full erection to the end of coitus (1). Sexual
dysfunction is difficulty experienced by an individual or a
couple throughout any phase of normal sexual activity, in-
cluding physical pleasure, desire, preference, arousal, or
orgasm (2). Sexual dysfunction can have a profound im-
pact on a person’s perceived quality of sexual life (3).
Opiate abuse has increased in prevalence in recent
years throughout the world, especially in Iran (4, 5). Opium
and its derivatives have a long history in Iranian tradition,
so that pharmacological, psychotropic effects found in
people with difficulties (6). Research indicates that opium
was the first drug used by 46.4% of the subjects (7). Al-
though opium use has been reported in Iran for centuries,
it has evolved into a complex matter involving widespread
psychosocial, familial, and economic consequences. There
is no clear evidence of the actual number of drug abusers
in Iran. However, some reports estimate a probable pres-
ence of two to four million people. In addition, the cur-
rent, formally announced number of drug abusers in Iran
is about two million (8, 9).
Methadone maintenance therapy (MMT) is a well-
known method of treating dependence on opioid raw ma-
terials and, in particular, is used to decrease the damage
caused by these substances (10). Methadone has two enan-
tiomeric forms: the racemic formula is used more regu-
larly (11). MMT has been the foundation of pharmacologic
management of opiate dependence (12-15). Methadone, a
synthetic sedative drug used for the treatment of opium
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addiction, is also used instead of morphine and hydromor-
phone for patients suffering from severe pain (16).
Sexual dysfunction is a common and clinical side ef-
fect of heroin misuse and opiate-substitute treatment, be-
cause opium can cause atrophy and declining libido (17).
Chronic opiate addicts experience sexual dysfunction in-
cluding reduced libido and sexual performance in males
and females, erectile dysfunction and delayed ejaculation
in males (18), and amenorrhea and reduced fertility in fe-
males (19-24). These side-effects are often neglected and,
therefore, unexplored in the routine clinical care of opiate
addicts. Yet, they are highly clinically related, as they could
lead to non-adherence to treatment (25).
Research indicates that heroin and methadone cause
a drop in testosterone levels in males. Plasma testos-
terone levels have been revealed to be lower in opiate ad-
dicts, as compared with controls (26). Patients on lower
doses of heroin and methadone have been found to have
higher testosterone levels (27). In addition, various stud-
ies have shown the effect of heroin and methadone on
testosterone levels in males. Other explanations offered
to clarify opiate-induced sexual dysfunction include the
a-adrenergic blocking activity of opiates, which may di-
rectly influence the functioning of accessory sex organs,
and psychological factors, such as sedation, euphoria, and
a chaotic lifestyle in addicts that inhibits sexual desire and
performance. These patients may prefer drug-procuring
behaviors to opportunities for sexual encounters (20, 28).
Sexual dysfunction is a common problem among ad-
dicted Iranian opiate users who undergo MMT, but only a
few studies on sexual dysfunction of methadone-treated
patients have been undertaken in Iran and other countries.
As a result, the importance of sexual dysfunction has been
underestimated. Research studies in other countries have
found that up to 87% of women and 85% of men who enter
MMT have reported sexual difficulty while using opium.
However, many patients with sexual dysfunction do
not report this issue to clinicians and many clinicians
sense discomfort among patients about dealing with sex-
ual problems. Of the few Iranian studies conducted on sex-
ual dysfunction, Tatari et al. (2013) (29), in their study of 157
drug-dependent subjects, found the prevalence of erectile
function to be 60.5% and sexual desire to be 70.7%. A study
on the prevalence of erectile function among 201 Italian
patients at seven methadone and buprenorphine mainte-
nance treatment centers revealed that 24% of patients re-
ported mild to moderate erectile dysfunction, and 18% re-
ported severe erectile dysfunction (30).
The paucity of research on sexual dysfunction among
patients on MMT in Iran and in other countries is a cru-
cial concern. Assessment of sexual dysfunction in these
patients is important, because identification and man-
agement of sexual dysfunction can increase compliance
with the treatment procedure, the effectiveness of which
is associated with more doses and a longer duration of
treatment (31). The present study is designed to examine
the prevalence of sexual dysfunction and to investigate
whether there is a change in sexual dysfunction following
six months of MMT, compared with baseline.
Previous studies reported the prevalence and kinds of
sexual dysfunction in men on MMT for opioid dependence
and described factors that may contribute to sexual dys-
function. While ED is not life-threatening, it may result in
withdrawal from sexual intimacy and reduced quality of
life (26).
Among the side-effects of heroin misuse and opiate-
substitute treatment, sexual dysfunction is common and
clinically significant. This is often ignored and, therefore,
unknown in the routine clinical care of opiate addicts. Yet,
it is yet highly clinically relevant, as it could lead to lack
of adherence to treatment. Sexual dysfunctions noted in
chronic opiate addicts include reduced libido and sexual
performance in males (32), erectile dysfunction and de-
layed ejaculation (18), and amenorrhea and reduced fertil-
ity in females (20, 33).
Various assumptions have been used to explain sex-
ual dysfunction in male opiate abusers. Cushman and
Kreek (1972) (28) reported a negative correlation between
high-dose methadone and low plasma testosterone lev-
els. Apart from the effect of heroin and methadone on re-
ducing testosterone levels in males, other causes used to
explain opiate-induced sexual dysfunction include the a-
adrenergic blocking activity of opiates, which may directly
influence the functioning of accessory sex organs.
Psychological factors, such as sedation, euphoria, and
the chaotic lifestyle of addicts can impair sexual desire
and performance, and these patients often prefer drug-
procuring behaviors to opportunities for sexual encoun-
ters. Several studies have identified a range of sexual dys-
functions in male patients addicted to heroin and those
treated with methadone (34).
2. Objectives
In this study, we assessed the sexual functioning of
male heroin users undergoing MMT.
3. Patients and Methods
3.1. Patients and Procedures
Patients were recruited from outpatient attendees at
several MMT centers between June 2015 and February 2016.
Male patients aged between 25 and 50 years, with a DSM-5
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diagnosis of opiate dependence syndrome, who were de-
pendent on heroin or were being prescribed methadone,
were included in the study. Patients on methadone were
required to have been using it for at least six months. The
target was a sample size of 150 methadone users, and all se-
rial attendees at the clinic were interviewed until this num-
ber was reached.
Patients were excluded from the study if they had any
of the following: comorbid alcohol dependence, a chronic
physical disorder, such as diabetes mellitus, hypertension,
chronic pain, endocrine or urologic disorders, or rheuma-
toid arthritis. Participants were asked not to use antide-
pressants, neuroleptics, antipsychotics, sedatives, anxi-
olytics, or antiandrogens during the study, because of the
negative effects of these medications on sexual function
and the possibility of interference with the study process
and goals. Participants in whom comorbidities were de-
tected, including drug or alcohol use, severe hypertension
or stress, hormonal problems due to medical or surgical
conditions such as testicular surgery, or who suffered from
neurological or metabolic problems or diabetes were ex-
cluded, because of the negative effects of these problems
on the study procedure.
The interviews were conducted in quiet, comfortable
settings. Each interview lasted approximately one hour.
All eligible patients (on the basis of self-reports of drug
use) were then subjected to a urinalysis for psychoactive
substances to confirm their use of heroin and methadone
and to exclude concurrent use of other psychoactive sub-
stances. A final number of 150 patients participated in the
study.
3.2. Interview and Administrative Tools
A semi-structured interview was administered, which
included questions on socio-demographics, drug use de-
tails, and sexual behavior. Next, the International Index of
Erectile Function (IIEF-15) was administered upon admis-
sion to MMT (35).
The IIEF-15 is a reliable, multidimensional scale test
that explores various aspects of sexual dysfunction (36).
The test is self-administered and has 15 questions that ex-
amine 5 scales of erectile function, orgasmic function, sex-
ual desire, intercourse satisfaction, and overall satisfac-
tion. Maximum mean scores for the IIEF-15 are 75, and the
maximum mean score for each scale is as follows: erectile
function [30], orgasmic function [10], sexual desire [10], in-
tercourse satisfaction [15], and overall satisfaction [10]. On
the erectile function sub-scale, lower scores show worse
erectile dysfunction, and higher scores indicate less dys-
function. The reliability and validity of IIEF-15 were stan-
dard in Iran in the study on the Farsi international index of
erectile dysfunction and doppler ultrasonography, which
evaluated male impotence (37).
The sexual self-efficacy scale–erectile functioning (SSES-
E) is a short self-report measure of the cognitive aspect of
erectile functioning and adjustment in men. It evaluates a
man’s attitudes about his sexual and erectile competence
in a variety of conditions. The scale may be fulfilled by a
man to obtain self-ratings or by his partner to obtain veri-
fication. Self-efficacy refers to confidence in the belief that
one can perform a certain task or behave adequately in a
given situation (38). Sexual self-efficacy is of great concern
to most men and a topic of increasing interest within an
aging population.
The SSES-E yields a self-efficacy strength score obtained
by summing the values in the Confidence column and di-
viding by 25 (the number of activities rated). Any activity
not checked in the Can Do column is presumed to have a 0
confidence (i.e., strength) rating. Some are reluctant to use
the 10-point interval, so any continuous number recorded
may be used in the Confidence column. Higher scores indi-
cate greater confidence in the man’s erectile competence
(39).
3.3. Statistical Analysis
The statistical method used to analyze the data was
the Mann-Whitney U test to reveal the changes that partici-
pants reported in their SD at admission to MMT (baseline),
compared with six months of methadone treatment (post-
assessment).
4. Results
The study included 150 married males who were be-
tween 25 and 50 years old (mean: 35.48; SD = 7.91). The
majority of participants was employed and had education
levels of diploma (n = 68; 45.3%) or bachelor’s degree (n
= 50; 33.3%). Participants were on methadone, with the
dose gradually increasing. Results showed that age, edu-
cation, employment, and methadone treatment duration
were not associated with sexual dysfunction prevalence (P
> 0.05).
The baseline erectile dysfunction mean score on the
IIEF was 15.55, which showed a moderate prevalence
for erectile dysfunction among participants after taking
methadone that positively increased to 18.12 in the post-
assessment. Further analysis showed that the baseline or-
gasmic function score was 5.42, which increased moder-
ately to 6.98 in the post-assessment (Table 2). The base-
line sexual desire score was 4.66, which increased moder-
ately to 5.90 in the post-assessment. Further analysis re-
vealed a slight improvement in sexual desire among par-
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Table 1. General Characteristics of the Methadone Study Patients




25 - 30 54 36
31 - 40 55 36.66





Secondary School 34 16
Diploma 68 45.3
Bachelor’s 50 33.3




History of Drug Use











ticipants after taking methadone, compared with base-
line (Table 2). The baseline overall satisfaction score was
4.79, which increased moderately to 5.85 in the post-
assessment. The baseline erectile functioning (SSES-E)
score was 86.71, which increased moderately to 94.34 in the
post-assessment. Further analysis revealed overall sexual
satisfaction and erectile functioning (SSES-E) among par-












Figure 1. Erectile Function Before and After MMT
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Figure 4. Sexual Desire Before and After MMT
5. Discussion
This study showed that erectile dysfunction and other
sexual dysfunctions have a very high prevalence in opioid-
dependent males. Among men on MMT, 65% had erec-
tile dysfunction (ED) and 27% had moderate to severe ED,
72.66% of whom were men younger than 40 and 27.34% of
whom were aged 40+. The frequency of erectile dysfunc-
tion in the overall population is about 16.1% (40, 41).
One of the reasons for non-adherence to treatment
with agonists useful in MMT relates to concerns about its
sexual side-effects. We have found that sexual dysfunc-
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Table 2. IIEF Scores of Erectile Dysfunction and Related Sexual Aspects in Baseline and After Six Months of Maintenance Treatment (MMT) (n = 150)
Variable Pre-Assessment, Mean± SD Post-Assessment, Mean± SD U Z P Value
Erectile function 15.55± 2.08 18.12± 2.06 289.000 2.44 0.009
Orgasmic function 5.42± 3.89 6.98± 2.67 263.000 3.57 0.015
Sexual desire 4.66± 3.12 5.90± 2.40 245.000 2.39 0.017
Overall satisfaction 4.79± 2.76 5.85± 3.22 236.000 3.17 0.001








Figure 5. Overall Satisfaction Before and After MMT
tion is a common problem among opiate-dependent pa-
tients who are referred for treatment (30, 42). In the cur-
rent study, the severity of some aspects of sexual dysfunc-
tion among participants decreased moderately after six
months of extensive methadone treatment. Results indi-
cated that orgasmic dysfunction was moderately preva-
lent. The research of Palha and Esteves (2002) (43, 44),
who studied sexual dysfunction among 101 heroin addicts,
found that 60% of men in their study had problems achiev-
ing orgasm. They also found that 75% of men in their
study complained of low libido, 71% reported altered sex-
ual arousal, and 72% had reduced sexual satisfaction. Addi-
tional treatment, such as androgen replacement therapy,
might be necessary. In addition, these difficulties might
have been the result of a variety of psychological and in-
terpersonal factors not reported by participants.
Drug addiction is a nearly universal problem and cri-
sis. This phenomenon has crossed geographical borders
and destroyed many lives (45). Some scholars believe that
addiction is the result of urban development, such as in
the first and third regions in central Isfahan city (46). Pub-
lic participation plays an important role in reducing this
problem (23, 47, 48). Within Isfahan city, there are three ur-
ban social factors that can help reduce drug addiction (49):
urban spirit assessment and its value to the city center (50),
artistic and musical activities and creating a happy envi-
ronment (51), and encouraging youth to know the history
and traditions of their country and to feel proud of their
culture (52).
5.1. Conclusion
In the present study, sexual problems slightly im-
proved after participants took methadone. The long-term
side-effects of opioid dependence on decreased libido were
likely to be related to the core features of sexual desire and
overall satisfaction. These possibly required additional
therapies or could have been attributable to the disrupted
affective and sexual relationship of participants with their
spouses, requiring psycho-intervention, sex therapy, or
marital therapy.
Several limitations existed in this study. This was cross-
sectional research, without a control group, hormone as-
say, or monthly evaluation by IIEF-15. We used baseline sex-
ual status to compare with post-assessment results of sex-
ual function among participants. It was methadone use
and improvement in sexual dysfunction from our obser-
vations in this pilot study. Additional studies with larger
samples and lower dropout rates are necessary. Further-
more, our data was based on self-reporting, which lacked
objective evidence. However, we administered the IIEF-15,
which is recognized as the gold standard for evaluating
sexual dysfunction (53). We evaluated sexual dysfunction
at an appropriate time, in the sixth month, when our ex-
tensive interviews with patients showed they frequently
reported having adjusted to both the methadone dose and
treatment conditions in the MMT program.
The present study found no relationship between de-
mographics, drug use history, and duration of MMT to im-
provement in sexual dysfunction. Nevertheless, a higher
methadone dose and longer duration of MMT, in compar-
ison with a low dose and shorter treatment duration in
experimental and control groups, are subjects for future
studies on sexual dysfunction in male patients, particu-
larly given that some well-known studies have claimed the
reverse effects of methadone treatment on certain aspects
of sexual function, such as libido and orgasmic function
(26).
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Sexual dysfunction is an important concern for many
patients undergoing MMT, and a good opiate use treat-
ment program must address this issue. Androgen replace-
ment (54) and pharmacological treatment may be effective
approaches for these patients, while psycho-intervention
for patients and counseling programs for couples may be
useful (55-57).
This study showed that erectile dysfunction and other
sexual dysfunctions have a very high prevalence in opioid-
dependent males. This subject has drawn insufficient at-
tention and is still unknown as a public health issue. In
turn, this problem has its own effects on patients’ health
and damages the prognosis for recovery from drug abuse.
Moreover, addiction withdrawal centers are linked to this
facet of patients’ health. Therefore, they should be fore-
warned about the side-effects and dysfunctions caused by
opioids. In addition, explaining to addicts that methadone
causes fewer complications than using illegal drugs can
help prevent premature exit from MMT. Moreover, this
matter should be recognized as a means of preventing ad-
diction in the future.
Footnote
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